

KIMIABL/COMP/BSE/23-24/ 67

Date: 14.02.2024

To,
Corporate Relationship Department
BSE Limited
P.J. Towers
1st Floor, New Trading Ring
Dalal Street, Mumbai- 400001.

Ref: BSE Scrip Code: 530313 and Scrip ID: KIMIABL
Sub: Outcome of Board Meeting

Dear Sir/ Madam,

The meeting of the Board of Directors was held on Wednesday, February 14, 2024 at 3:00 pm (IST), and the following businesses, amongst others, were transacted thereat:

1. Approval of un-audited financial results, on standalone basis, of the Company for the quarter and nine months ended December 31, 2023 in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taking on record the Limited Review Report of the Auditors on the same (copy attached as **Annexure A**)

You are requested to take the above information on record and disseminate the same on your website.

The meeting concluded at 7.30 p.m.

Thanking you.

Yours faithfully,
For Kimia Biosciences Limited


Lakshay Prakash
Company Secretary & Compliance Officer

Place: New Delhi



KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana -122102
Tel.: +91 9654746544, 9654206544

Corporate Office

974, 9th Floor, Aggarwal Millenium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

1/3

S. No.	Particulars	Quarter ended			Nine month Ended		Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,614.46	2,420.01	2,880.24	7,457.48	10,585.30	12,851.60
II	Other Income	57.63	63.74	26.40	133.89	85.00	121.31
III	Total Income (I+II)	2,672.09	2,483.75	2,906.64	7,591.37	10,670.30	12,972.91
IV	Expenses:						
a)	Cost of materials consumed	2,018.14	970.43	2,673.81	4,879.49	8,922.23	10,639.34
b)	Change in inventories of finished goods and work-in-progress	(60.99)	872.75	(452.15)	710.09	(1,107.74)	(1,036.22)
c)	Employee benefits expenses	383.20	389.52	397.71	1,171.42	1,151.81	1,640.30
d)	Finance costs	131.12	111.92	104.91	370.62	298.41	424.50
e)	Depreciation and amortisation expense	81.88	82.31	84.29	247.40	246.40	333.23
f)	Other expenses	378.85	383.47	556.16	1,161.27	1,580.16	2,105.77
V	Total Expenses (IV)	2,932.20	2,810.40	3,364.73	8,540.29	11,091.27	14,106.92
VI	Profit/(loss) before exceptional items and Tax (III-V)	(260.11)	(326.65)	(458.09)	(948.92)	(420.97)	(1,134.01)
VII	Exceptional Items	(260.11)	(326.65)	(458.09)	(948.92)	(420.97)	(1,238.81)
VI	Profit/(loss) before tax (IV-V)						
VII	Tax expenses:						
a)	Current Tax	-	-	-	-	-	-
b)	Deferred Tax charge / (credit)	(64.93)	(82.48)	(112.01)	(238.52)	(102.28)	(303.59)
VIII	Profit/(loss) for the period (VI-VII)	(195.18)	(244.17)	(346.08)	(710.40)	(318.69)	(935.22)
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-	(7.33)
	- Remeasurement of defined benefit plans	-	-	-	-	-	-
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-	(942.55)
X	Total Comprehensive Income for the period (VIII+IX)	(195.18)	(244.17)	(346.08)	(710.40)	(318.69)	473.13
XI	Paid up equity share capital (Face value of Rs. 1 per equity share)	473.13	473.13	473.13	473.13	473.13	73.15
XII	Other Equity						
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	(0.41)	(0.52)	(0.73)	(1.50)	(0.67)	(1.98)
	Diluted in Rs.	(0.41)	(0.52)	(0.73)	(1.50)	(0.67)	(1.98)

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- During the financial year 22-23, a penalty of ₹104.80 Lakhs was imposed by the Haryana State Pollution Control Board for non-compliance with certain regulations. The same has been provided in above results and disclosed as exceptional item.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th February, 2024.



FOR KIMIA BIOSCIENCES LIMITED
 Sameer Goel
 (Managing Director & CEO)
 DIN - 00161786

Date: February 14, 2024
 Place: New Delhi

Independent Auditor's Review Report on Unaudited Financial Results for the quarter and nine months ended December 31, 2023 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended

To the Board of Directors of Kimia Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Biosciences Limited ("the Company") for the quarter and nine months ended December 31, 2023, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Noida (Delhi — NCR)
Date: February 14, 2024



For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E


Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 24088926BKELUK7039